Have a specific question about your LBP project? Click below and let’s get started.
June 22, 2026
By: List Labs
C. difficile Toxin A and Toxin B: Roles in CDI Research, Diagnostics, Vaccines, and Therapeutics By Stacy Burns-Guydish, PhD, and John Neville, PhD List Labs Clostridioides difficile infection is primarily driven by toxin-mediated damage caused by toxin A and toxin B, also known as TcdA and TcdB. These toxins are central to CDI pathogenesis and [...]
September 19, 2022
By: List Labs
List Labs is an experienced contract development and manufacturing organization (CDMO) harnessing bacteria’s potential for a healthier world. We offer a refreshingly flexible approach to clients seeking a CDMO for Live Biotherapeutic Products (LBP) derived from beneficial bacteria. Partner with List Labs as your CDMO and experience our uniquely collaborative and transparent culture. Why Choose […]